Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. (NASDAQ: KIDS) is an orthopedic medical device company focused exclusively on pediatric orthopedics, and its news flow reflects this specialization. Company announcements frequently cover revenue updates, financial guidance, and quarterly earnings, where OrthoPediatrics discusses performance across its trauma and deformity, scoliosis, and specialty bracing (OPSB) product lines, as well as metrics such as the number of children treated with its systems.
Readers following KIDS news can expect regular updates on financial results and outlook, including preliminary unaudited revenue releases, full quarterly earnings reports, and adjustments to annual guidance. These releases often highlight contributions from specific product categories, trends in domestic and international revenue, and management’s commentary on operational initiatives such as restructuring efforts and cost management.
OrthoPediatrics also issues news on product development and regulatory milestones. Recent examples include FDA approval of the 3P Pediatric Plating Platform Small-Mini System, additional FDA clearances within a single year, and EUMDR certification for spine, trauma, and deformity implants and instruments. The company reports on first clinical procedures with new systems, such as the VerteGlide Spinal Growth Guidance System for early onset scoliosis, and on portfolio expansions like new PediHip bracing products within OPSB.
In addition, KIDS news includes strategic and corporate updates, such as distribution partnerships (for example, with MY01 for Continuous Perfusion Sensing Technology), expansion of OPSB clinics and territories, participation in healthcare and investor conferences, and changes to the board of directors. Investors and observers who monitor this news stream gain insight into how OrthoPediatrics is evolving its pediatric orthopedic platform, broadening its product offering, and engaging with clinicians and the capital markets.
OrthoPediatrics (NASDAQ: KIDS) has announced a major milestone in its Global POISE (Pediatric Orthopedic Implant Safety and Efficacy) Study, with over 600 implants now being monitored across more than 300 pediatric patients.
The multi-center, post-market, prospective clinical follow-up study, launched in 2023, now includes 13 active sites across Canada, the United States, Australia, New Zealand, and South Africa. The study encompasses 17 different implant types and aims to assess the safety and efficacy of OrthoPediatrics' implant devices, focusing on implant survival and identifying device-related adverse events.
OrthoPediatrics (NASDAQ: KIDS) announced its continued role as the exclusive Emerald Sponsor for the 2025 Pediatric Orthopaedic Society of North America (POSNA) annual meeting. The company will showcase its expanding pediatric-specific solutions, including OrthoPediatrics Specialty Bracing and Enabling Technologies, across three exhibit booths. As part of its long-term commitment to POSNA, OrthoPediatrics provides support through specialty symposiums, educational grants, and scholarships for attendees.
OrthoPediatrics (NASDAQ: KIDS) has announced the expansion of its Trauma and Deformity portfolio with the 3P™ Pediatric Plating Platform™ Hip System, marking the company's 5th FDA approval in 2025. This innovative plate and screw platform aims to modernize trauma and deformity correction treatment in lower extremities.
The beta launch of 3P Hip will be followed by 3P Small/Mini in early 2026, with additional systems planned for future release. This initiative represents one of the company's largest product developments in its Trauma and Deformity division, aimed at creating the most comprehensive modern plating portfolio in pediatric orthopedic history.
OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced it will release its first quarter 2025 financial results on May 7, 2025, after market close. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.
Investors can access both the live and archived webcast of the earnings call through the Events & Presentations section of the company's website at www.orthopediatrics.com. The webcast recording will remain available for at least 90 days following the event.
OrthoPediatrics (Nasdaq: KIDS) has announced the U.S. launch of the VerteGlide Spinal Growth Guidance System, marking their 80th system for treating pediatric musculoskeletal conditions. The system, recently FDA-cleared, is designed to treat Early Onset Scoliosis (EOS) in children under 10 years old who often experience pulmonary and digestive dysfunction.
The VerteGlide system aims to correct deformity while minimizing repeat surgeries until skeletal maturity. Initial surgeries are expected to begin at select children's centers during summer 2025. The technology was developed in partnership with pediatric orthopedic surgeons Dr. Richard McCarthy and Dr. Scott Luhmann, utilizing Shilla™ technology licensed from Medtronic.
OrthoPediatrics (Nasdaq: KIDS), a company specializing in pediatric orthopedics, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's leadership team, including President & CEO Dave Bailey and COO/CFO Fred Hite, will engage in a fireside chat during the conference.
Investors and interested parties can access the audio webcast of the discussion through OrthoPediatrics' investor relations website at http://ir.orthopediatrics.com, with a replay option available after the event.
OrthoPediatrics (Nasdaq: KIDS) has been named one of the 2025 Best Places to Work in Indiana for the 9th time by the Indiana Chamber of Commerce. The pediatric orthopedics-focused company joins 150 other organizations from over 20 industries across the state in this 20th edition of the recognition program.
Company President & CEO David Bailey emphasized their commitment to fostering an engaging and inclusive culture, highlighting continuous investments in employee development and meaningful career experiences. The recognition reflects the company's success in building a positive workplace environment focused on helping children.
Indiana Chamber President Vanessa Green Sinders noted the program's importance in evaluating workplace culture amid intense talent competition. The final rankings will be revealed at an awards ceremony on April 30th, 2025, followed by publication in the Chamber's BizVoice® magazine.
OrthoPediatrics (Nasdaq: KIDS) has announced its partnership with the Crossroads Pediatric Device Consortium (CPDC), a multi-institutional initiative focused on accelerating pediatric medical device development. The consortium includes Purdue University's Weldon School of Biomedical Engineering, the Indiana University School of Medicine's Department of Pediatrics, and Cook Medical.
This collaboration aims to strengthen the consortium's capabilities in developing and commercializing pediatric medical devices, particularly in orthopedics. The partnership leverages OrthoPediatrics' specialized expertise in pediatric orthopedics to enhance the consortium's innovative potential.
The CPDC's distinctive model integrates major medical device companies to streamline product development, regulatory navigation, and commercialization processes, ensuring efficient transition of pediatric medical innovations from concept to market.
OrthoPediatrics (NASDAQ: KIDS) reported strong financial results for Q4 and full year 2024. The company achieved record annual revenue of $204.7 million, up 38% from 2023, with domestic revenue increasing 45% and international revenue growing 15%.
Q4 2024 highlights include total revenue of $52.7 million, a 40% increase year-over-year, and adjusted EBITDA of $3.0 million, more than double compared to Q4 2023. The company helped over 34,000 children in Q4 and approximately 138,000 for the full year.
Key segment performance for 2024:
- Trauma and Deformity revenue: $145.1 million (+36%)
- Scoliosis revenue: $55.2 million (+45%)
- Sports Medicine/Other: $4.4 million (+11%)
For 2025, OrthoPediatrics projects revenue between $235.0-242.0 million, representing 15-18% growth, and expects adjusted EBITDA of $15.0-17.0 million.